Table 1:
Azithromycin (AZ) Treatment Allocation.
| Group | Number of injections | Post-HI treatment (h after end of HI) | N | Deaths |
|---|---|---|---|---|
| LPS+HI a: 3 (AZ*3) vs. 5 (AZ*5) dose regimens b | ||||
| Saline | 5 | 2, 24, 48, 72, 96 | 15 | 1 |
| AZ*3 | 3 | 2, 24, 48 | 16 | 2 |
| AZ*5 | 5 | 2, 24, 48, 72, 96 | 16 | 1 |
| LPS+HI a: Initial-dose time-dependence of AZ*5 neuroprotection | ||||
| Saline | 5 | 2, 24, 48, 72, 96 | 12 | 4 |
| AZ*5 1h | 5 | 1, 24, 48, 72, 96 | 12 | 0 |
| AZ*5 2h | 5 | 2, 24, 48, 72, 96 | 12 | 0 |
| AZ*5 4h | 5 | 4, 24, 48, 72, 96 | 12 | 0 |
| PAM+HI c: 3 (AZ*3) vs. 5 (AZ*5) dose regimens b | ||||
| Saline | 5 | 2, 24, 48, 72, 96 | 8 | 2 |
| AZ*3 | 3 | 2, 24, 48 | 8 | 0 |
| AZ*5 | 5 | 2, 24, 48, 72, 96 | 8 | 1 |
| PAM+HI c: Initial-dose time-dependence of AZ*5 neuroprotection | ||||
| Saline | 5 | 2, 24, 48, 72, 96 | 5 | 1 |
| AZ*5 1h | 5 | 1, 24, 48, 72, 96 | 6 | 0 |
| AZ*5 2h | 5 | 2, 24, 48, 72, 96 | 5 | 0 |
| AZ*5 4h | 5 | 4, 24, 48, 72, 96 | 5 | 0 |
a:
LPS+HI: Lipopolysaccharide (LPS, 0.05 mg/kg) was injected i.p., 2.5 h prior to right carotid artery ligation; 1.5 h later, exposure to 50 min 8% O2 began.
b:
AZ*3: 45, 22.5, 22.5 mg/kg/dose; AZ*5: 45, 22.5, 22.5, 22.5, 22.5 mg/kg/dose. Saline and AZ injections were i.p.
c:
PAM+HI: The synthetic lipopeptide TLR2 agonist Pam3Cys-Ser-(Lys)4 (PAM, 0.5 mg/kg) was injected i.p. 4.5 h prior to right carotid artery ligation, and 1.5 h later, exposure to 60 min 8% O2 began.